ELRIG Strengthens Board with New Appointments to Drive Growth

ELRIG, a not-for-profit organisation serving the global drug discovery community, has announced the appointment of Dr Kelly Gray and Dr Elaine Duncan to its Board. This strategic move is aimed at enhancing ELRIG’s scientific programmes and early-career initiatives. With over 22,000 life science professionals in its network, ELRIG’s growth is poised to meet the evolving needs of the biopharma, biotech, academia, and industry sectors.

Dr Kelly Gray, an innovation leader with extensive experience in life sciences, will lead ELRIG’s Scientific Programme Work Group. Her background includes a PhD from the University of Cambridge and a pivotal role at AstraZeneca in Open Innovation. Dr Gray’s new role involves developing a strategic annual programme of scientific conferences and ensuring impactful global outreach. Meanwhile, Dr Elaine Duncan, a postdoctoral researcher from the University of Glasgow with a commitment to STEM, will lead the Early Career Professionals Work Group. She aims to increase engagement among early-stage professionals through targeted strategies and communications. Both appointees have been active members of ELRIG’s General Committee, bringing fresh perspectives and continuity to the organisation’s leadership.

By welcoming Dr Gray and Dr Duncan to its Board, ELRIG reinforces its commitment to advancing scientific innovation and supporting early-career scientists. Their expertise and enthusiasm will be instrumental as ELRIG continues to support life science research and collaboration, ultimately driving positive developments in drug discovery.